DC-SIGN from African green monkeys is expressed in lymph nodes and mediates infection in trans of simian immunodeficiency virus SIVagm. by Ploquin, MJ et al.
JOURNAL OF VIROLOGY, Jan. 2004, p. 798–810 Vol. 78, No. 2
0022-538X/04/$08.000 DOI: 10.1128/JVI.78.2.798–810.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
DC-SIGN from African Green Monkeys Is Expressed in Lymph Nodes
and Mediates Infection in trans of Simian Immunodeficiency
Virus SIVagm
Mickae¨l J.-Y. Ploquin,1 Ousmane M. Diop,2 Nathalie Sol-Foulon,3 Lorenzo Mortara,1†
Abdourahmane Faye,2 Marcelo A. Soares,1‡ Eric Nerrienet,4 Roger Le Grand,5
Yvette Van Kooyk,6 Ali Amara,7§ Olivier Schwartz,3 Franc¸oise Barre´-Sinoussi,1
and Michaela C. Mu¨ller-Trutwin1*
Unite´ de Biologie des Re´trovirus,1 Virus et Immunite´,3 and Unite´ d’Immunologie Virale,7 Institut Pasteur, Paris,
and CEA, Fontenay aux Roses,4 France; Laboratoire de Re´trovirologie, Institut Pasteur, Dakar, Senegal2; Centre
Pasteur du Cameroun, Yaounde´, Cameroon5; and Department of Molecular Cell Biology, Free
University Medical Center, Amsterdam, The Netherlands6
Received 19 June 2003/Accepted 3 October 2003
African green monkeys (AGMs) infected by simian immunodeficiency virus (SIV) SIVagm are resistant to
AIDS. SIVagm-infected AGMs exhibit levels of viremia similar to those described during pathogenic human
immunodeficiency virus type 1 (HIV-1) and SIVmac infections in humans and macaques, respectively, but
contain lower viral loads in their lymph nodes. We addressed the potential role of dendritic cell-specific
intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN; CD209) in viral dissemination. In previous
studies, it has been shown that human DC-SIGN and macaque DC-SIGN allow transmission of HIV and
SIVmac to T cells. Here, we looked at the ability of DC-SIGN derived from AGM lymph nodes to interact with
SIVagm. We show that DC-SIGN-expressing cells are present mainly in the medulla and often within the cortex
and/or paracortex of AGM lymph nodes. We describe the isolation and characterization of at least three
isoforms of dc-sign mRNA in lymph nodes of AGMs. The predicted amino acid sequence from the predominant
mRNA isoform, DC-SIGNagm1, is 92 and 99% identical to the corresponding human and rhesus macaque
DC-SIGN amino acid sequences, respectively. DC-SIGNagm1 is characterized by the lack of the fourth motif
in the repeat domain. This deletion was also detected in the dc-sign gene derived from thirteen animals
belonging to five other African monkey species and from four macaques (Macaca fascicularis and M. mulatta).
Despite three- to seven-amino-acid modifications compared to DC-SIGNmac, DC-SIGNagm1 allows transmis-
sion of SIVagm to T cells. Furthermore, AGM monocyte-derived dendritic cells (MDDC) expressed at least
100,000 DC-SIGN molecules and were able to transmit SIVagm to T cells. At a low multiplicity of infection
(105 50% tissue culture infective doses/cell), viral transmission by AGM MDDC was mainly DC-SIGN
dependent. The present study reveals that DC-SIGN from a natural host species of SIV has the ability to act
as an efficient attachment and transmission factor for SIVagm and suggests the absence of a direct link
between this ability and viral load levels in lymph nodes.
Dendritic cells (DC) residing in mucosal tissues are among
the first cells targeted by human immunodeficiency virus
(HIV) and simian immunodeficiency virus (SIV) SIVmac dur-
ing pathogenic infections in humans and macaques, respec-
tively (22, 51). DC can transmit these viruses to T cells in vitro
(6, 17, 40). One mechanism by which DC enhance infection of
T cells implies DC-SIGN (DC-specific ICAM-3-grabbing non-
integrin; CD209) (9, 13). DC-SIGN, a C-type (calcium-depen-
dent) lectin, has been detected on monocyte-derived DC
(MDDC). It also facilitates the formation of the immunologi-
cal synapse between DC and T cells by binding to intercellular
adhesion molecule 3 (ICAM-3) (14). In addition, HIV bound
to DC-SIGN-positive cells can be transmitted to cells express-
ing CD4 and a coreceptor, resulting in efficient virus infection
in trans (13, 38). DC-SIGN cannot replace CD4, CCR5, or
CXCR4 in the process of HIV type 1 (HIV-1) entry but retains
infectious particles for several days in culture (13) in a low-pH
endosomal compartment (27). Similarly, DC-SIGN from ma-
caques also acts as an attachment factor for SIVmac (2, 12, 25,
61). In addition, coexpression of human DC-SIGN with CD4
and an appropriate coreceptor can enhance infection of HIV
and SIVmac in cis (28).
HIV-1 is thought to subvert the trafficking capacity of DC to
gain access to the CD4-T-cell compartment (19, 42, 53). It
has been shown that SIVmac-infected DC are able to migrate
from original sites of infection to draining lymph nodes (LNs)
(22). Similar to “Trojan horses,” DC-SIGN expressing DC may
serve as a shuttle for the transfer of HIV-1 from submucosa to
secondary lymphoid organs (13, 52). During the formation of
the immunological synapse with T cells, it is possible that
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infected DC then transmit the virus to permissive T cells within
the secondary lymphoid organs (6, 18, 30, 40, 60).
To understand the role of DC-SIGN in viral dissemination
to LNs and pathogenesis, we studied the function of DC-SIGN
in a nonhuman primate model in which infection with a lenti-
virus is nonpathogenic. SIVagm infection in all four species of
African green monkeys (AGM, Chlorocebus pygerythrus, C. ae-
thiops, C. sabaeus, and C. tantalus) is associated with a lack of
disease, although the associated viremia levels in plasma can
reach those described for pathogenic HIV-1 and SIVmac in-
fections (5, 10, 16, 21). In contrast to plasma viremia, the DNA
and RNA viral loads in LNs of SIVagm-infected AGMs are
generally significantly lower than those reported for HIV and
SIVmac pathogenic infections (4, 5, 10). Here we examined
whether potential structural and functional differences be-
tween DC-SIGNagm and human DC-SIGN and/or differences
in the expression levels underlie the low viral load in AGM
LNs.
MATERIALS AND METHODS
Animals and specimen collection. The AGMs—C. sabaeus, C. tantalus, and C.
pygerythrus—were kept in captivity at the Pasteur Institute in Senegal, at the
Pasteur Institute in Bangui (Central African Republic), and at the Centre In-
ternational de Recherches Me´dicales, in Franceville (Gabon), respectively. Patas
monkeys (Erythrocebus patas) were held in captivity at the Pasteur Institute in
Bangui. L’Hoest’s monkeys (Cercopithecus lhoesti lhoesti), white-collared manga-
beys (Cercocebus torquatus lunulatus), gray-cheeked mangabeys (Cercocebus al-
bigena), and a naturally SIVcpz-infected chimpanzee (Pan troglodytes, Cam5)
were housed in European and Cameroonian zoos (33, 34). Rhesus (Macaca
mulatta) and cynomolgus (M. fascicularis) macaques were housed at the primate
center of CEA, Fontenay aux Roses, France. All animals were held according to
national guidelines and institutional policies. For the studies on genomic DNA,
peripheral blood mononuclear cells (PBMC) of these nonhuman primates were
Ficoll gradient purified, and total DNA was isolated. All of the studies on the
characterization, the expression levels, and the function of DC-SIGN were per-
formed with AGMs of the C. sabaeus species (animals 96028, 97008, 97026,
97029, 00017, 00021, 02001, 02007, 02008, 02013, and 02026). These animals
were negative for SIV, except for 97026 and 98013, which were experimentally
infected with SIVagm.sab92018 (10). Blood was collected from these animals,
and excisional inguinal and axillar LN biopsies were performed. For AGMs
97026 and 98013, the axillar LNs were collected at days 7 and 120 postinfection,
respectively.
Virus stocks. We collected PBMC from the naturally SIVagm-infected animal
D46 (32). SIVagm.sabD46 was isolated by coculture of the PBMC with SUPT1
cells, a human lymphoblastoid T-CD4-cell line. For HIV-1, we used an HIV-
1Lai isolate that was cultured on SUPT1 cells. Virus production was followed by
the measurement of core antigens (SIV p27 and HIV p24; Coulter) and of
reverse transcriptase activity in the supernatants. The infectious viral titer was
determined by a limiting-dilution assay with SUPT1 cells as described previously
(10). The infectious titer was expressed as the 50% tissue culture infectious dose
(TCID50) determined by the Karber calculation method. The titers of HIV-1Lai
and SIVagm.sabD46 stocks were 250 and 400 TCID50/ml, respectively. Concen-
trations of core antigens for HIV-1Lai and SIVagm.sabD46 stocks were 1,700 and
860 ng/ml, respectively.
Cells and cell lines. SupT1 cells were cultured in RPMI 1640 with Glutamax
(Invitrogen) supplemented with 10% fetal calf serum (FCS), penicillin-strepto-
mycin (100 IU/ml each) and HEPES (10 mM; Invitrogen). HeLa cells were
maintained in Dulbecco modified Eagle medium with Glutamax (glucose, 1,000
mg/liter; Invitrogen) supplemented with 10% FCS (Invitrogen), penicillin-strep-
tomycin (100 IU/ml each), and HEPES (10 mM; Invitrogen). P4P cells are CD4
CXCR4 CCR5 HeLa cells (59). These cells were maintained in the culture
medium described above supplemented with puromycin (1 g/ml; Sigma) and
Geneticin G418 (0.5 mg/ml; Invitrogen).
To obtain MDDC, we first enriched monocytes from PBMC of human donors
and of AGMs by a 1-h 30-min plastic adhesion step at 37°C, followed by extensive
washing in prewarmed FCS-free culture medium in order to remove all nonad-
herent cells. The adherent cells were then cultured in RPMI 1640 supplemented
with 5% FCS, granulocyte-macrophage colony-stimulating factor (1,000 IU/ml;
Leucomax [Novartis]) and interleukin-4 (IL-4; 200 IU/ml; R&D Systems) for 4 to
5 days. The phenotype of the cells was checked by flow cytometry. The cells
expressed the molecules typically found on immature MDDC, such as CD11c,
major histocompatibility complex class II (DR), CD80, and CD86 (unpublished
data). The purity of the cells was95% as measured by anti-CD3 and anti-CD20
labeling.
Isolation and sequencing of dc-signagm mRNA. Total mRNA of LN cells
derived from AGM 96028 and 97026 was extracted and then reverse transcribed
and amplified in one step by reverse transcription-PCR (RT-PCR; Superscript
One-Step RT-PCR System; Invitrogen). The primers used for the RT-PCR step,
designed by using a previously published human dc-sign cDNA sequence (9),
were MDC1 (forward, 5-CAGGAGTTCTGGACACTG-3) and MDC2 (re-
verse, 5-GATGGAGAGAAGGAACTGTAG-3). To detect potential minor
amplicons, we subjected the amplification products obtained by RT-PCR to a
nested PCR. The primers used for the nested PCR were MDC3 (forward,
5-CTGGGGGAGAGTGGGGTG-3) and MDC4 (reverse, 5-CTTAAAAGG
GGGTGAAGTTC-3). Annealing of primers occurs on the 5 and 3 ends of the
coding region. Cycling conditions were as previously described (10). After the
nested PCR, the amplicons were gel purified (gel extraction kit; Qiagen) and
subcloned (TOPO TA Cloning kit; Invitrogen). The sequences were determined
for both strands (BigDye terminator cycle sequencing ready reaction kit; Perkin-
Elmer).
PCR on genomic DNA. Total DNA was extracted from simian cells and
submitted to PCR by using the primers DCS-EX4S (forward; 5-CCCAGCTCC
ATAAGTCAGGAACAA-3) and DCS-EX4AS (reverse; 5-ACACAACGACC
ATCTCAGGCCCAAG-3). Annealing of primers occurs on the 5 part of exon
III and the 5 part of intron III of dc-sign when the organization of the human
gene is considered (35). Cycling conditions were as previously described (10).
Assessment of DC-SIGNagm-mediated infection in trans. The efficiency of
DC-SIGNagm-mediated virus transfer was first assessed by using human cell
lines. Nonpermissive HeLa cells were transduced transiently with an expression
vector (pcDNA3.1/myc-his) containing either dc-signagm1 or dc-signhu cDNA (20)
or with vector alone by using the Polyfect transfection reagent (Qiagen). After
48 h, the level of expression of DC-SIGN at the cell surface was determined by
flow cytometry by using two mouse monoclonal antibodies (MAbs), 8A5 and
1B10, raised against DC-SIGNhu. 1B10 recognizes the carbohydrate recognition
domain (CRD) and was described previously (20). Transduced-nonpermissive
HeLa cells (5  105 cells) were exposed to low infectious doses of virus (multi-
plicity of infection [MOI] of 104 or 105 TCID50/cell). DC-SIGNhu- and
DC-SIGNagm1-expressing cells were exposed for 2 h at 37°C to HIV-1Lai and to
SIVagm.sabD46, respectively. The cells were then vigorously washed. After 24 h,
cells were washed again and cultured with SupT1 cells (HeLa/SupT1 ratio 0.5),
permissive to both HIV-1Lai and SIVagm. Virus production was determined by
measuring HIV p24 or SIV p27 core antigens in the supernatants. For inhibition
of transmission, viral exposure was performed as described above after the cells
were stained with neutralizing MAb 1B10 at 50 g/ml (15 min, 4°C), 5 mM
EGTA (Sigma), or mannan (Sigma) at 50 g/ml.
To examine the capacity of primary AGM cells to transfer virus to T cells, 105
AGM MDDC were incubated with SIVagm.sabD46 (MOI of 103, 104, or 105
TCID50/cell) for 3 h at 37°C in a 5% CO2 incubator. As a positive control, we
used human MDDC. After exposure to the virus, AGM and human MDDC were
extensively washed with prewarmed Hanks balanced salt solution, resuspended
in culture medium containing granulocyte-macrophage colony-stimulating factor
and IL-4, and either immediately cocultured with permissive SupT1 cells or after
3 days washed again extensively and cocultured with SupT1 (MDDC/SupT1 ratio
 0.5). At 3- to 4-day intervals, supernatants were harvested and tested for core
antigen by enzyme-linked immunosorbent assay to monitor virus replication. For
inhibition assays, AGM MDDC were incubated with 65 g of anti-DC-SIGNhu
MAb (1B10) or control mouse immunoglobulin G2a (IgG2a)/ml for 20 min at
4°C prior to the addition of SIVagm.sabD46. AGM MDDC were also treated
with mannan (50 g/ml) prior to the addition of SIVagm.sabD46. To inhibit viral
replication, 10 M zidovudine (AZT; Sigma) was added to the MDDC 3 h before
their exposure to virus and maintained until the start of the coculture with SupT1
cells. We have previously shown that 5 M AZT blocks infection in human
macrophages (29). In addition, it has been shown that 10 M AZT inhibits
HIV-1 replication in human Langerhans cells (24).
Quantification of DC-SIGN molecules. MDDC were stained in phosphate-
buffered saline supplemented with 2% FCS for 45 min at 4°C with an anti-DC-
SIGNhu MAb, 1B10, at a final concentration of 65 g/ml. The samples were
washed and incubated with phycoerythrin-Cy5-conjugated goat anti-mouse Fab
fragments (Dako; 1/20) for 15 min at 4°C and then washed and resuspended in
buffer containing 1% paraformaldehyde. The samples were analyzed with an
EPICS XL (Coulter) cell analyzer. For quantification, we used the Quantum
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Simply Cellular microbead kit (Sigma). The quantification was performed by
converting the mean fluorescence intensity (MFI) into the antibody-binding
capacity (ABC) per cell. For this, the kit contains a mixture of five microbead
populations of uniform size, coated with goat anti-mouse antibodies that have
different abilities to bind mouse antibodies (i.e., ranging from 0 to 215,000
molecules). All samples, including the microbeads, were processed separately
and analyzed identically. The binding capacities of the stained microbeads were
then regressed against the corresponding MFI of each microbead population.
The MFI of the antigen analyzed on the cells was converted to ABC per cell by
comparison with the regression curve generated. The MFIs of the samples were
corrected by subtracting the MFI of the isotype control for each experiment, and
the value was then converted to the ABC. This technology can accurately mea-
sure ABC values up to ca. 215,000. Values in excess of this amount fell outside
of the standard values. Therefore, they should not be deemed as definitive.
Immunohistochemical analysis. Sections (5 m) of cryopreserved OCT-em-
bedded tissues were analyzed by immunohistochemistry to determine whether
DC-SIGN is expressed on cells in AGM LNs and to study the distribution of
DC-SIGN cells within this tissue. Immunostaining was performed with the
anti-DC-SIGN MAb clone 8A5 (2.4 g/ml) or clone 1B10 (6.5 g/ml), as well as
with the anti-CD68 MAb (clone EBM11; Dako). Immunostaining with primary
mouse antibody was revealed by using Dako EnVision horseradish peroxidase
conjugated to a secondary antibody. Diaminobenzidine was used as a high sen-
sitivity chromogenic substrate system. The slides were counterstained with Har-
ris’s hematoxylin for coloration of nuclei.
Nucleotide sequence accession numbers. The sequences of the cloned DC-
SIGNagm1, DC-SIGNagm2, and DC-SIGNagm3 have been deposited in Gen-
Bank under accession numbers AY189945, AY189946, and AY189947, respec-
tively. The nucleotide sequence of dc-signagm1 cDNA from AGM 97026 differs
from that of AGM 96028 only by three synonymous mutations (data not shown).
The latter sequence has been deposited in GenBank under the accession number
AY189944.
RESULTS
Isolation and sequence of dc-signagm mRNA from AGM LNs.
In order to assess the role of DC-SIGN in SIVagm infection,
we first determined whether dc-sign mRNA is expressed in
AGM LNs. Axillary and inguinal LNs were obtained from two
AGMs (animals 96028 and 97026). Animal 96028 was negative
for SIV, whereas 97026 had been experimentally infected with
SIVagm.sab92018 (10). Total mRNA was extracted from LNs.
Since a wide repertoire of transcripts of the human dc-sign has
been reported (35), we designed a nested PCR to amplify
potential minor transcripts of the dc-sign gene within AGM
LNs. We detected a predominant 1,150-bp amplicon after a
single round of PCR, as well as additional fragments with
smaller sizes after the nested PCR (data not shown). Sequence
analyses revealed three distinct cDNAs. Alignment of the pre-
dicted amino acid sequence of the predominant isoform,
named DC-SIGNagm1, with DC-SIGNhu (9) and DC-SIGNmac
(M. mulatta, allele 1) (2) revealed identities of 92.08 and 98.95%,
respectively (Fig. 1A). The N-linked glycosylation sites (NxT/S)
(38) and internalization motifs, such as LL and YxxL (50), as well
as the transmembrane domain, are conserved in DC-SIGNagm1.
The minor transcripts, called dc-signagm2 and dc-signagm3, both
differ from dc-signagm1, dc-signhu, and dc-signmac by the absences
of (i) exon Ic, encoding a small region in the cytoplasmic tail
(CT); (ii) exon III, encoding the repeat domain (RD); and (iii)
the 5 part of exon IV encoding the first 40 amino-acids of the
CRD (Fig. 1). dc-signagm2 and dc-signagm3 may have arisen from
complex alternative splicing. Although transcripts encoding mem-
brane-associated isoforms characterized by the deletion of exons
III and IV have been described for humans, none showed a
deletion of exon Ic (35). Furthermore, we have not detected
mRNA deletions in exon II (TM) which could encode potentially
soluble proteins. The latter have been detected in several human
cells such as PBMC, DC derived from CD34 peripheral blood
hematopoietic progenitors, and resting CD14 human monocytes
(35). Finally, all DC-SIGNagm isoforms differ from DC-SIGNhu
by the absence of 23 amino acids within the RD, corresponding to
the fourth motif (Fig. 1).
Deletion within the region coding for the RD of the dc-
signagm gene. To determine whether the presence of 6.5 instead
of 7.5 motifs is the result of differential splicing or a deletion in
exon III (exon IV according to Soilleux et al. [48]) encoding
the repeat region (35), we performed PCR on genomic DNA
from AGM 96028 with primers annealing to the 5 part of exon
III and the 5 part of intron IV. The expected size for the
human fragment is 587 bp. The fragments amplified from
AGM 96028 DNA were about 70 nucleotides shorter than
those obtained from human DNA (Fig. 2), indicating that the
lack of the fourth motif in the cDNA resulted from a deletion
in the dc-sign gene rather than from alternative splicing.
Deletion in the dc-sign gene present in animals from 10
distinct Old World monkey species. To study the frequency of
occurrence of the deletion of the fourth motif in AGMs, we
performed PCR on genomic DNAs from 28 other wild-born
AGMs belonging to three distinct AGM species. The study
included 22 SIVagm-infected animals. We also studied
genomic DNA from the commonly used AGM cell line Vero,
derived from a vervet. The same deletion was observed in
DNAs from each AGM tested, as well as in DNA from Vero
cells (Fig. 2).
Among African nonhuman primates studied to date, only
dc-sign mRNA from one chimpanzee has been analyzed so far
and it failed to show this deletion (12). In order to determine
whether this deletion in exon III is present or not in other
African nonhuman primates, we examined genomic DNA of 13
animals from five distinct species: patas monkey (Erythrocebus
patas), l’Hoest monkey (Cercopithecus lhoesti), white-collared
mangabey (Cercocebus torquatus lunulatus), gray-cheeked
mangabey (Cercocebus albigena), and chimpanzee (Pan troglo-
dytes troglodytes) (33). The latter corresponds to a naturally
SIVcpz-infected chimpanzee (Cam5) (34). We observed again
a smaller amplicon, indicating the same deletion in all of the
animals studied (Fig. 2).
Since a deletion of this fourth motif was reported in DC-
SIGN from macaques by some authors, whereas others did not
observe it (2, 12, 44, 61), we analyzed genomic DNA from four
macaques (two M. fascicularis and two M. mulatta macaques of
Chinese origin). Again, only fragments of smaller sizes com-
pared to the human fragment were detected in all four studied
macaques. Our study therefore suggests that the allele with the
6.5 motifs in exon III is more frequent than the allele with the
7.5 motifs in Old World nonhuman primates, at least in those
of African origin.
Reactivity of DC-SIGNagm1 with anti-DC-SIGNhu MAbs.
To study the function of DC-SIGN from AGM, we first ana-
lyzed DC-SIGNagm expression with MAb as a molecular tool.
HeLa cells were transfected transiently with an expression
vector (pcDNA3.1/myc-his) containing either dc-signagm1 or
dc-signhu cDNA (20) or with vector alone. After 48 h, the level
of expression of DC-SIGN at the cell surface was analyzed by
flow cytometry using two mouse MAbs, 8A5 and 1B10 (20),
raised against DC-SIGNhu. Cells transfected with either dc-
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FIG. 1. (A) Alignment of predicted amino acid sequences of DC-SIGNagm1, DC-SIGNagm2, and DC-SIGNagm3 with reported sequences of
DC-SIGNhu and DC-SIGNmac. The sequence of DC-SIGNhu (9) and the third reported sequence of DC-SIGN isolated from a macaque (M. mulatta)
(61) wree used for the alignment. The three isoforms isolated from animal AGM 97026 are shown. The The dileucine (LL) and YxxL internalization
motifs are in boldface. The fourth repeat motif is indicated in italics. Arrows above the sequences highlight the different domains of DC-SIGN: CT,
cytoplasmic tail; TM, transmembrane; and ND, neck domain. Dots and dashes indicate, respectively, conserved amino acids and deletions. (B) Schematic
representation of DC-SIGNagm1, DC-SIGNagm2, and DC-SIGNagm3. DC-SIGNhu and DC-SIGNmac were represented as proposed by Po¨hlmann et
al. (38). Note that DC-SIGNagm and DC-SIGNmac (2, 12, 44, 61) are characterized by the lack of the fourth motif repeat within the RD, in contrast
to DC-SIGNhu. DC-SIGNagm isoforms 2 and 3 are characterized by the absence of exon III coding the RD and of the exon IV region encoding the 5
part of the CRD. DC-SIGNagm2 also exhibits the absence of exon Ic encoding a small region in the CT.
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signagm1 or dc-signhu cDNA stained positive, showing that both
MAbs are cross-reactive against DC-SIGNagm from AGMs
(Fig. 3). The staining was always higher in percentage and
fluorescence intensity for DC-SIGNhu than for DC-SIGNagm
due to either more efficient transfection and/or better affinity
of the MAbs for DC-SIGNhu. Similar results were obtained
with another MAb raised against DC-SIGNhu, AZND1 (13;
data not shown).
DC-SIGNagm1 ability of SIVagm transmission to T cells.
The presence of a shorter RD in DC-SIGN in both macaques
and AGMs indicates that it cannot, by itself, be responsible for
potential functional differences in viral transmission. However,
DC-SIGNagm1 also differs by at least three amino acids from
DC-SIGN of M. mulatta (Fig. 1A) and by seven amino acids
from DC-SIGN of M. nemestrina (2, 12, 44, 61). Several dif-
ferences were located within the CRD that is known to be
involved in binding to HIV/SIVmac (15, 38). The CRD of
DC-SIGNagm1 differs by at least one amino acid from the
rhesus macaque CRD (Fig. 1A) and by three amino acids from
the pigtailed macaque CRD (2). To evaluate whether any of
these amino acid differences in DC-SIGNagm1 could affect its
function as a viral attachment and transmission factor, we
determined whether DC-SIGNagm1-expressing cells could
transmit SIVagm to T cells
dc-signagm1 transiently transduced nonpermissive HeLa cells
were exposed to low infectious doses of virus (MOIs of 104
and 105 TCID50/cell). DC-SIGNhu and DC-SIGNagm1 ex-
pressing cells were, respectively, exposed to HIV-1Lai and
SIVagm.sabD46. After 24 h, cells were washed again and cul-
tured with a human T-cell line (SupT1) permissive to both
HIV-1 and SIVagm. As a positive control, we first confirmed
the ability of DC-SIGNhu to mediate HIV-1 infection in trans
(Fig. 4A). We then tested the properties of DC-SIGNagm. We
consistently detected efficient SIVagm replication in SupT1
cells cultured with HeLa cells expressing DC-SIGNagm1 but
not in SupT1 cells cultured with HeLa cells transfected with
vector alone (Fig. 4B). Similar results were observed with an-
other SIVagm.sab virus, SIVagm.sab92018 (data not shown).
Moreover, transmission was largely inhibited by EGTA, a
known inhibitor of C-type lectin-binding activity (Fig. 4C). The
transmission was also inhibited by using mannan or an MAb
raised against DC-SIGNhu, 1B10 (data not shown). These
experiments demonstrate that DC-SIGNagm1 mediates trans-
mission of SIVagm to T cells.
Coexpression of DC-SIGNagm1 along with CD4 and an
appropriate coreceptor on HeLa cells enhances 3-fold SIVagm
infection by permissive cells (data not shown). DC-SIGNagm1
therefore enhances infection in cis.
DC-SIGN expression on AGM MDDC. After we showed
that the dc-sign mRNA in LNs codes for an efficient attach-
ment and transmission molecule for SIVagm, we attempted to
analyze whether primary AGM cells would be able to transmit
SIVagm to T cells. We therefore determined whether AGM
MDDC express DC-SIGN. Staining of AGM MDDC with
MAb 1B10 revealed that DC-SIGN is expressed on their sur-
face (Fig. 5A).
It has been shown that the transmission efficiency depends
on the expression levels of DC-SIGN and that 60,000 mole-
cules per cell are necessary for efficient viral transmission (38).
We therefore measured DC-SIGN expression on AGM
MDDC by using a quantitative cell cytometry technology. The
number of surface molecules on MDDC was determined for
six SIVagm-seronegative AGM and six HIV-1-seronegative
donors. All AGM and human MDDC studied expressed at
least 100,000 molecules per cell. On AGM and human MDDC,
respectively, we found a median of 168,000 (range, 118,000 to
517,000) and 244,000 (range, 141,000 to 347,000) DC-SIGN
copies/cell (Fig. 5B). Statistical analysis did not reveal any
significant differences between the levels of DC-SIGN expres-
sion on the analyzed AGM and human MDDC (Mann Whit-
ney, P  0.2623). The molecule numbers rather varied accord-
ing to the donors, to similar degrees in humans and AGMs.
Similar variations have also been previously reported in an-
other study on human MDDC (1).
Capacity of AGM MDDC to transmit SIVagm to T cells and
implication of DC-SIGN. To determine whether AGM MDDC
are able to transmit SIVagm to T cells, MDDC from two
animals (97008 and 02001) on which the level of DC-SIGN
expression had been assessed (516,000 and 166,000 copies/cell,
respectively) were exposed to SIVagm (MOI of 103 TCID50/
cell). It has been reported that DC-SIGN THP-1 human
MDDC efficiently retain infectious HIV particles for 4 days
(13). To increase the specificity of our assay, we increased the
time between viral exposure and coculture with SupT1 cells by
two more days compared to the assay with HeLa cells. MDDC
were thus cultured with SupT1 cells only 3 days after viral
exposure and after repeated washings. In parallel to AGM
MDDC we treated human MDDC under the same experimen-
tal conditions. We detected a viral replication only in SIVagm-
exposed human MDDC cocultured with SupT1 but not in
SIVagm-exposed human MDDC alone (Fig. 6A). Thus, we
show that human MDDC are able to transmit SIVagm. Fur-
thermore, AGM MDDC are capable to transmit SIVagm to T
cells (Fig. 6A). In AGM MDDC cultured alone, again we did
not detect signs of SIVagm replication, as measured by p27
quantification in supernatants.
In order to further increase the specificity of the assay and to
work with infectious doses even closer to physiological condi-
tions in vivo, we also tested viral transmission by AGM MDDC
FIG. 2. Amplification of the genomic region coding for the RD in
simian and human dc-sign genes. PCR was performed with genomic
DNA of 30 AGMs (14 C. sabaeus, 13 C. tantalus, 2 C. pygerythrus, and
Vero cells), 4 patas monkeys (Erythrocebus patas), 2 l’Hoest monkeys
(Cercopithecus lhoesti), 5 white-collared mangabeys (Cercocebus tor-
quatus lunulatus), 1 gray-cheeked mangabey (Cercocebus albigena), 1
naturally SIVcpz-infected chimpanzee (Cam5), 2 rhesus macaques (M.
mulatta), 2 cynomolgus macaques (M. fascicularis), and 1 human do-
nor. Representative results obtained for one individual of each species
and for nine AGMs are shown. The primers used were designed to
amplify exon III encoding the RD, corresponding to a 587-bp fragment
of the human dc-sign gene. Lanes: MW, molecular weight; 1, AGM,
Sab96028; 2, AGM, C. sabaeus; 3, AGM, C. sabaeus; 4, AGM, C.
sabaeus; 5, AGM, C. pygerythrus; 6, AGM, C. pygerythrus; 7, AGM, C.
tantalus; 8, AGM, C. tantalus; 9, AGM, Vero cells; 10, Erythrocebus
patas; 11, Cercopithecus lhoesti lhoesti; 12, Cercocebus torquatus lunula-
tus; 13, Cercocebus albigena; 14, Pan troglodytes troglodytes; 15, M.
mulatta; 16, M. fascicularis; H, Homo sapiens sapiens.
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with 104 and 105 MOI of SIVagm.sab. This assay was per-
formed with MDDC derived from two animals (02007 and
02008) for which the number of DC-SIGN molecules ex-
pressed on their surface had also been determined (118,000
and 170,000 copies/cell, respectively). Due to the limitation of
the amount of blood that can be taken from the animals, which
are about 20 times smaller than humans, the number of gen-
erated DC is low. Consequently, it was impossible to perform
all experiments with DC from a same animal. However, each
assay was always repeated with at least two donors. AGM
MDDC were again able to transmit SIVagm to T cells (Fig. 6B
and C).
To address whether this SIVagm transmission was due to
DC-SIGN, the MDDC derived from the two latter animals
were also exposed to SIVagm.sab (MOIs of 104 and 105
TCID50/cell) in the presence of an anti-DC-SIGNhu MAb
(1B10) or mannan. The latter is the most potent saccharide
inhibitor of DC-SIGN (9). The presence of mannan reduced
significantly SIVagm transmission at MOIs of 104 (60% in-
hibition) and 105 (85% inhibition) (data not shown). The
presence of an anti-DC-SIGN MAb reduced the trans infection
of T cells by MDDC of both animals. The inhibition was 40%
and 60 to 95% at MOIs of 104 and 105, respectively (Fig. 7).
At the lower MOI (105), the viral transmission was thus
FIG. 3. Cross-reactivity of anti-DC-SIGNhu MAbs toward DC-SIGNagm1. HeLa and P4P cells, transiently expressing DC-SIGNhu or
DC-SIGNagm1, were stained 48 h posttransfection with anti-DC-SIGNhu MAbs (either 8A5 or 1B10). On all histograms, the dotted curve
represents staining with an isotype control antibody (IgG2a), whereas the black curve represents DC-SIGN staining. The percent positive cells and
MFIs are indicated. The results obtained were similar with HeLa and P4P cells. One of four representative experiments with HeLa cells is shown.
Both MAbs were cross-reactive with DC-SIGNagm1.
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mainly DC-SIGN dependent. In order to confirm the observed
results, we repeated the experiment at an MOI of 105 with
MDDC from two other animals (00017 and 02026). Again, we
observed significant inhibition (70%) of transmission (Fig. 7).
Consequently, AGM MDDC sufficiently express high numbers
of DC-SIGN molecules, retain SIVagm particles in an infec-
tious state for at least 3 days after viral exposure, and promote
SIVagm transmission to T cells through a mechanism that
preferentially involves DC-SIGN when low doses of virus are
used.
Nevertheless, at the lower MOI (105 TCID50/cell), the anti-
DC-SIGN MAb failed to completely abolish viral transmission.
One explanation might be the implication of others molecules
with trans attachment activity (56). Another explanation could
be that SIVagm productively infects AGM MDDC which could
FIG. 4. Ability of DC-SIGNagm to transmit SIVagm to T cells.
Nonpermissive HeLa cells transiently expressing DC-SIGN were ex-
posed to low infectious doses of virus (MOIs of 104 and 105) and
cocultured for 24 h postexposure with SupT1 cells. Viral replication
was determined by measuring the viral core antigen in supernatants
every 2 or 3 days (HIV-1 p24 and SIV p27; Coulter). The results
obtained with a virus MOI of 104 are shown. Experiments were
performed in duplicate. The values measured at day 3 or 4 and day 6
of coculture are indicated. The results of one representative experi-
ment of three is shown. We used HeLa cells transiently transduced
with vector alone as a negative control. (A) Transmission of HIV-1Lai
by DC-SIGNhu. (B) Cells transfected with vector containing
dc-signagm1 cDNA or vector alone were exposed to SIVagm.sabD46.
(C) The DC-SIGNagm1-expressing cells were exposed to SIVagm.s-
abD46 in the presence of 5 mM EGTA in order to test whether
transmission of SIVagm from HeLa to SupT1 cells is dependent on
Ca2, a feature consistent with a C-type lectin activity. EGTA was
added during the 2-h exposure of cells to the virus. P27 levels detected
at day 6 of a 10-day culture are shown.
FIG. 5. Quantitative measurement of DC-SIGN on MDDC. Im-
mature MDDC were obtained from six uninfected AGM donors and
six healthy human donors. We quantified the surface expression level
of DC-SIGN by using a MAb raised against DC-SIGNhu (1B10) and
a phycoerythrin-Cy5-coupled goat F(ab)2 anti-mouse antibody in con-
junction with the Quantum Simply Cellular microbead kit (Sigma).
(A) DC-SIGN expression on AGM and human MDDC. On all histo-
grams, the dotted curve represents staining with an isotype control
antibody (IgG2a), whereas the solid curve represents DC-SIGN stain-
ing. (B) The values are expressed as the ABC per cell for each animal
and each human donor. Each value is represented by a symbol, and
horizontal bars show the median value.
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result in high virus replication in cocultures through infection
of T cells independently of DC-SIGN, explaining the failure to
completely inhibit viral transmission with anti-DC-SIGN MAb.
We were not able to detect any significant production of SIV
p27 antigen in the 14-day cultures of MDDC exposed to
SIVagm.sab (Fig. 6), but we cannot exclude a very low level of
virus replication undetectable by the enzyme-linked immu-
nosorbent assay. To address this question, we performed two
kind of approaches. First, we added the T cells immediately
after exposure of MDDC to SIVagm to allow viral transmis-
sion before any potential viral de novo synthesis and compared
p27 production to that determined when the T cells were
added 3 days after virus exposure. The viral production in T
cells cocultured immediately with MDDC was either higher
(animal 00021) or equal to the levels observed in T cells cocul-
tured 3 days after the SIVagm-exposure of MDDC (animal
97007) (Fig. 8A). The lower levels we detected if we cocultured
MDDC with Supt1 after 3 days might be explained by a po-
tential degradation of virus particles, as shown for HIV-1 par-
ticles (36). In any case, the 3-day time frame was associated
with an increase of viral replication in DC-T cocultures. This
suggested that, if low-level de novo synthesis of viral particles
occurs within the 3-day period, it does not significantly add to
viral transmission.
In order to confirm this, we blocked viral replication with an
RT inhibitor. MDDC from two animals were treated with AZT
during the 3 days before the start of the coculture. We ob-
served that AZT treatment of MDDC did not reduce viral
transmission compared to levels of viral replication in medium-
treated MDDC (Fig. 8B). For both animals, levels of viral
replication in DC-T cocultures were similar whether the DC
were treated with AZT or not. We confirmed that virus trans-
mission after 3 days is efficient even after treatment with AZT
for MDDC from two further AGM donors (data not shown).
Thus, virus transmission is efficient in the absence of early de
FIG. 6. Assessment of SIVagm transmission by MDDC. Immature
AGM MDDC were exposed to SIVagm.sabD46 (MOIs of 103, 104,
and 105 TCID50/cell). Three days later, the cells were washed and
cocultured with SupT1 cells. We exposed, in parallel, human MDDC
to SIVagm.sabD46 (MOI of 103 TCID50/cell). The experiments were
performed in duplicate. Virus production after the start of the cocul-
ture was monitored by SIV p27gag antigen assay. Plain and broken lines
indicate levels of SIV p27gag antigen in the MDDC-SupT1 cocultures
or in the cultures of MDDC alone, respectively. (A) SIVagm.sab trans-
mission by AGM and human MDDC. The MDDC were exposed to a
virus MOI of 103. (B) Transmission by AGM MDDC exposed to
SIVagm at an MOI of 104. (C) Transmission by AGM MDDC ex-
posed to SIVagm at an MOI of 105.
FIG. 7. Inhibition of SIVagm transmission by AGM MDDC with
an anti-DC-SIGNhu MAb. AGM MDDC were exposed to SIVagm
.sabD46 in the presence of anti-DC-SIGNhu (1B10), a control IgG2a,
or medium alone. Each experiment was performed in duplicate. In
order to express percentage of inhibition, the p27gag antigen values of
the IgG2a-treated cells, obtained for day 14, were normalized to 100%.
The results obtained with MDDC from two AGM (animals 02007 and
02008) exposed to MOIs of 104 and 105 of SIVagm are shown. The
results obtained with MDDC from two further animals (00017 and
02026) exposed to an SIVagm MOI of 105 are also presented here.
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novo synthesis. These experiments also indicate that infectious
particles are maintained at least 3 days in AGM MDDC.
In order to confirm the implication of DC-SIGN in viral
transmission, AZT-treated MDDC from four animals were
exposed to SIVagm in the presence of anti-DC-SIGN MAb
and cocultured with SupT1 cells 3 days after. In these condi-
tions viral transmission was reduced between 70 and 95% (Fig.
8C) showing again that the viral transmission was promoted in
a predominant DC-SIGN-dependent manner.
The presence of an RT inhibitor within the 3-day period thus
failed to significantly reduce viral transmission, indicating that
the failure to fully inhibit transmission by using an anti-DC-
SIGN MAb was not due to an undetectable productive infec-
tion of MDDC. These findings support data showing that other
molecules than DC-SIGN also contribute to viral transmission
(55–57) albeit, as we show here, to a lower degree than DC-
SIGN when low virus doses are used.
DC-SIGN-expressing cells in AGM LNs. Our data demon-
strate that AGM MDDC express high levels of DC-SIGN
comparable to human MDDC and that DC-SIGN plays the
main role in SIVagm transmission by AGM MDDC in the
presence of lower doses of virus. The study also revealed that
AGM LN cells abundantly express dc-sign mRNA, suggesting
that DC-SIGN is expressed at significant levels in LN in vivo.
To determine whether not only the mRNA but also the protein
is expressed on the surface of cells within LNs, we performed
immunohistochemistry analyses on LN sections derived from
two SIVagm uninfected AGMs (animals 02001 and 00021) for
which the level of DC-SIGN expression on MDDC had been
evaluated (166,000 and 238,000 copies/cell, respectively) and
from one chronically SIVagm-infected AGM (animal 98013).
We labeled the sections with two distinct anti-DC-SIGN MAb
(1B10 and 8A5) raised against to two distinct epitopes. The
distribution of the DC-SIGN cells was similar whatever the
MAb we used (data not shown). We detected DC-SIGN cells
mainly within the medulla (Fig. 9A) and often within the cortex
and/or paracortex (cortex/paracortex) in all three tested ani-
mals (Fig. 9A and data not shown). We did not detect any
differences in the distribution of DC-SIGN cells between
infected and uninfected animals (data not shown). DC-SIGN
cells both in the medulla and in the cortex/paracortex exhibited
an irregular morphology (Fig. 8C), and some DC-SIGN
round cells were present within medullary sinuses (a finding
consistent with sinusoidal macrophages) (data not shown). The
distribution and the morphology of the DC-SIGN cells in
AGM LNs were thus identical to that described in LNs of
macaques (8, 23, 45, 62). In rhesus macaques, it has been
previously described that in SIV-uninfected spleen and in SIV-
infected LN, DC-SIGN cells with dendritic morphology were
uniformly positive for the monocyte/macrophage lineage
marker CD68 (8, 45). The latter remains abundant even after
SIVmac infection (45). In AGM LNs, CD68 staining was also
abundant in medulla and cortex/paracortex areas. The distri-
bution of CD68 and DC-SIGN cells differed in germinal
centers (GC) (Fig. 9B). CD68 cells were present in GC,
whereas DC-SIGN cells remain always distributed outside
the GC (Fig. 9A and B). Numerous CD68 cells also exhibited
an irregular morphology (Fig. 9D).
FIG. 8. Viral transmission without lag time and in the absence of viral
replication between exposure of MDDC and coculture with T cells. AGM
MDDC were exposed to SIVagm.sabD46 (MOI of 105) and cocultured
with SupT1 cells. Each experiment was performed in duplicate. Virus
production was monitored by SIV p27gag antigen assay after the start of
the coculture. (A) Viral replication in DC-T cocultures started immedi-
ately or 3 days after exposure of MDDC to SIVagm. Solid and broken
lines indicate SIVagm replication in cocultures started immediately or
with a 3-day lag after viral exposure of MDDC, respectively. (B) Assess-
ment of AZT treatment of MDDC on viral transmission. DC-T cocultures
were started 3 days after exposure of MDDC from four animals to
SIVagm. An RT inhibitor (AZT) was added during the 3-day period to
inhibit any potential SIVagm replication in MDDC. Broken and solid
lines indicate MDDC treated with or without AZT, respectively. (C) Role
of DC-SIGN in viral transmission by AZT-treated AGM MDDC. AGM
MDDC from four animals treated with AZT before viral exposure and
during the 3-day period before the start of the coculture were exposed to
SIVagm in the presence of anti-DC-SIGNhu MAb (1B10), a control
IgG2a, or medium alone. In order to express the percent inhibition, the
p27gag antigen values of the IgG2a-treated cells, obtained for day 14, were
normalized to 100%.
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DISCUSSION
This is the first study that has analyzed the function of
DC-SIGN from a natural host species of SIV. Previous studies
have only reported interactions between DC-SIGN from hu-
man and rhesus macaques expressed on THP-1 or 293T cells
with HIV-luc pseudotyped with Env from SIVagm or SIVsm
(38, 61). Importantly, interactions of SIV with human mole-
cules or vice versa of HIV with simian molecules do not nec-
essarily reflect interactions of the virus with the homologous
host-specific molecule. It was shown, for instance, that
SIVmac, although able to use human STRL33/Bonzo, does not
efficiently use the macaque molecule for entry (39, 46). Simi-
larly, HIV-1 uses AGM CCR5 only inefficiently due to the
G163R difference between the human and AGM protein,
whereas SIVagm is adapted to efficiently use the wild-type
AGM CCR5 (26). It is thus important to analyze the interac-
tions of receptors and viruses derived from the same species.
Here we describe the efficient interaction between DC-SIGN
derived from AGMs (C. sabaeus) and its host-specific SIV
(SIVagm.sab). In order to be close to physiological conditions,
we used a viral isolate and not a molecular clone. Furthermore,
we performed infections with low viral doses (MOIs of 103 to
105). We showed on human cell lines that DC-SIGNagm can
act as a viral attachment factor like its human and macaque
counterparts despite structural differences among these mole-
cules. Consequently, this suggests that the lower viral load in
LNs during nonpathogenic SIVagm infection (10) compared to
pathogenic HIV/SIVmac infections (4, 5) cannot be explained
by structural differences in the AGM molecule. We cannot
totally exclude variations either among SIVagm strains or
among dc-signagm alleles that might be detected by analyzing
more donors. However, even if such variations exist, they could
not explain the consistently nonpathogenic outcome of
SIVagm infection.
In view of the above results, additional factors must be
involved in the low viral load in LNs during SIVagm infections.
Efficiency of transmission to T cells in vitro depends on the
levels of DC-SIGN and ICAM-1 expression on DC (38, 43).
Alternative splicing of dc-sign mRNA might represent a mech-
anism that could regulate the expression of the dc-sign gene.
Our study reveals a nonexhaustive repertoire of DC-SIGN in
LNs of AGMs. We have not detected dc-sign mRNA encoding
potentially soluble isoforms of DC-SIGNagm, whereas tran-
scripts coding for these isoforms have been detected by using
only a single RT-PCR step in human cells, such as PBMC, DC
derived from CD34 peripheral blood hematopoietic progen-
FIG. 9. DC-SIGN cells in AGM LNs. Sections (5 m) of cryopreserved OCT-embedded LN, harvested from two SIVagm-uninfected AGMs
and from one experimentally SIVagm-infected AGM (120 days postinfection), were incubated with anti-DC-SIGNhu MAb (8A5 and 1B10), with
anti-CD68hu MAb, or with control IgG2a. Staining was done by using horseradish peroxidase conjugated to a secondary antibody. Antigen staining
appears in brown. Sections were counterstained with Harris’s hematoxylin to stain nuclei, which appear in blue. Representative sections of axillary
LNs from the experimentally SIVagm-infected AGM stained with the anti-DC-SIGN clone 8A5 are presented here. (A and C) Staining with
anti-DC-SIGN (8A5); (B and D) staining with anti-CD68; (E) staining with the isotype control. Magnifications: 100 (A, B, and E), 400 (C and
D).
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itors, and resting CD14 monocytes (35). Indeed, the expres-
sion pattern of dc-sign transcripts may depend on the origin, as
well as the maturation or activation state, of the cells (35). It
remains unknown whether transcripts coding for potentially
soluble isoforms also exist in human LN or in other nonhuman
primates such as macaques. Although soluble isoforms do not
seem to be able to mediate enhancement of infection (27), they
may regulate expression of the membrane-associated forms of
DC-SIGN (35). However, we demonstrate here that AGM
MDDC show high surface-expressing levels of DC-SIGN pro-
tein. This contrasts with one study which reported very low
levels of DC-SIGN on rhesus macaque MDDC (61). The ex-
pression levels of DC-SIGN may vary according to the primate
species and/or the donor (25, 61). Numbers of DC-SIGN mol-
ecules on AGM MDDC did indeed vary according to the
AGM donor, as shown for human MDDC (1). However, the
AGM myeloid DC (MDDC) from all studied AGM donors
expressed at least 100,000 DC-SIGN molecules and often more
than 200,000 molecules per cell, a level sufficient to promote
viral transmission to T cells in vitro.
In vivo, DC-SIGN cells could be easily detected within the
medulla sinuses and the paracortex of AGM LNs. We cannot
exclude the possibility that the detection of positive cells in the
medulla sinuses could also be due to the related L-SIGN2 (3).
However, the distribution of DC-SIGN cells in the LNs of
AGMs was very similar to that described in macaques (8, 45,
62). Rhesus macaque antigen-presenting cells in the medulla
and cortex/paracortex in organized lymphoid tissues (LNs and
spleen) have been shown to express DC-SIGN, although the
number of positive cells has not been quantified (8, 45, 62).
The nature of the AGM DC-SIGN cells is unknown, but the
cells exhibited a morphology characteristic of DC. It has been
suggested in similar studies in humans and rhesus macaque
tissues that the DC-SIGN cells likely correspond to interdig-
itating DC and sinusoidal macrophages (14, 45, 49, 62). The
distribution of DC-SIGN cells in the medulla and paracortex
was similar to that of cells expressing a marker of the mono-
cyte/macrophage lineage (CD68). However, only CD68 cells
were detected in germinal center, showing that not all CD68
cells express DC-SIGN. Furthermore, it has been shown that in
macaque spleens and LNs all DC-SIGN cells exhibiting a
dendritic morphology express CD68 (45). Altogether, our data
show a similar morphology and distribution of DC-SIGN
cells compared to these cells in humans and macaques. We
also observed that mRNA coding for functional DC-SIGN is
abundantly expressed in AGM LNs. This suggests that DC-
SIGN expression on DC in AGM LN is not lower than in
humans and macaques.
We cannot totally exclude a distinct regulation of DC-SIGN
expression in response to SIVagm infection. The level of hu-
man DC-SIGN at the cell surface is indeed influenced by
HIV-1 proteins. A dramatic increase of lymphocyte adhesion
to HIV-1-infected DC in vitro due to an upregulation of DC-
SIGN mediated by Nef has been reported (50). This phenom-
enon, however, is not consistently observed for all donors (31).
It is not excluded that Nef encoded by SIVagm interacts dif-
ferentially with host-specific cellular proteins compared to
HIV/SIVmac Nef in human and macaque cells, which could
result in lower levels of DC-SIGN expression and/or lower
T-cell activation profiles in SIVagm-infected AGMs. Lower
T-cell activation states are indeed observed in nonpathogenic
SIV infections in their natural hosts (7, 11, 37, 47). However,
there are no signs thus far of SIVagm replication within AGM
MDDC with at least up to 103 TCID50/cell and after p27
values up to 2 weeks. This might also be dependent on the
SIVagm strains used. Further studies are needed to determine
the susceptibility of DC to SIV in nonpathogenic SIV infection
models.
Finally, the expression level might depend on the cytokine
environment in vivo after SIV infection. Several studies have
reported that IL-4 induces DC-SIGN expression on human
peripheral blood monocytes in vitro (35, 41). This IL-4-depen-
dent expression is negatively regulated by alpha interferon
(IFN-), transforming growth factor 	, and IFN-
 (41). Re-
cently, it has been shown in another model of nonpathogenic
SIVinfection, SIVsm infection in the sooty mangabeys, that the
chronic phase of infection is characterized by higher levels of
IL-4 and lower levels of IFN-
 production (47). Thus, there are
as yet no data that could support any downregulation of DC-
SIGN expression after SIV infection in the natural host.
We show here that MDDC from AGMs not only express
high levels of DC-SIGN but also efficiently transmit SIVagm to
T cells. This has been confirmed here for MDDC from 10
distinct AGM donors. Furthermore, as shown by inhibition
assays with anti-DC-SIGN MAb, viral transmission by AGM
MDDC is DC-SIGN dependent. This has been confirmed with
MDDC from six distinct AGM donors. This result supports the
findings of an earlier study of Chinese macaque species, M.
fascicularis, in which viral transmission is also largely DC-
SIGN dependent (25). However, it contrasts with a study of M.
mulatta MDDC that indicated no discernible role of DC-SIGN
in viral transmission (61). These controversial results might be
explained by variations of DC-SIGN expression according to
individuals, especially if only a few animals were studied,
and/or according to monkey species. Interestingly, we observed
that the viral transmission by AGM MDDC was significantly
blocked by anti-DC-SIGN MAbs only when a low MOI (105)
was used. It has been reported that the affinity of HIV-1 gp120
for DC-SIGNhu is higher than for CD4hu (9), and some data
suggested that it is also higher than for the mannose receptor
(56). Thus, the use of high viral infectious doses could probably
allow attachment to other molecules as well. This might also
explain why in previous studies anti-DC-SIGN MAb or man-
nan could not consistently block viral entry or Env/DC-SIGN
interaction in MDDC. Indeed, in these previous studies, very
high doses of HIV AD8 (MOI of 45) (57) or a high amount of
gp120 (twofold more than the predetermined concentration
for cellular saturation) (56) were used.
DC seem to be a “hiding place” for HIV-1 (58). However,
the mechanism of viral transfer via DC-SIGN has yet to be
fully elucidated. The function of DC-SIGN in the transmission
of HIV-1 depends on its cellular context (54). DC-SIGN ex-
pressed by DC or the monocytic cell line THP-1 but not 293
and HOS cells internalizes and retains HIV-1Bal in a highly
infectious state for more than 5 days (13, 54). Immature human
MDDC promote HIV-1Bal transfer by a mechanism that is
DC-SIGN dependent (40 to 100% according to the donors
tested) at least up to 2 days after viral exposure (54). Recently,
others suggest most endocytosed virus is already degraded
after 24 h (55). We demonstrated here that sufficient amounts
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of infectious SIVagm particles remain intact in AGM MDDC
up to 3 days, even when low doses of virus are used. This
efficiency might be due to the fact that we used a virus isolate
and MDDC to assess viral transfer to highly permissive T cells.
We analyzed here for the first time the virological functions
of DC-SIGN from an animal species resistant to AIDS. The
present study revealed similar activities for DC-SIGNagm re-
garding trans infection compared to previous reports on human
and macaque DC-SIGN. We demonstrated that DC-SIGN
cells are present in AGM LNs and that AGM MDDC express
levels of DC-SIGN similar to those expressed by human
MDDC. We showed that AGM MDDC are able to efficiently
transmit SIVagm to T cells. Finally, we showed that SIVagm
transmission is largely DC-SIGN dependent at low MOIs. Al-
together, our data indicate that the virus-binding properties of
DC-SIGN are not directly associated with viral load levels in
LNs. In conclusion, additional factors, such as the frequency in
LNs of major target cells (activated T CD4 lymphocytes), are
more likely determinating factors for viral replication levels in
LNs.
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